(Z)-5-(2'-(3'-(piperidinocarbonyl)thienylmethylidene))-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline | 864055-46-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (Z)-5-(2'-(3'-(piperidinocarbonyl)thienylmethylidene))-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline
• 英文别名: Piperidine amide, 6；[2-[(Z)-(9-hydroxy-10-methoxy-2,2,4-trimethyl-1H-chromeno[3,4-f]quinolin-5-ylidene)methyl]thiophen-3-yl]-piperidin-1-ylmethanone
• CAS: 864055-46-9
• 化学式: C₃₁H₃₂N₂O₄S
• 分子量: 528.672
• InChiKey: PLVITMXWYNPPHG-JLPGSUDCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  38
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  99.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (Z)-5-(2'-(3'-(piperidinocarbonyl)thienylmethylidene))-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline 在 三乙基硼氢化锂 、 水 、 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以80%的产率得到(Z)-5-(2'-(3'-hydroxymethylthienylmethylidene))-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline
  参考文献：
  名称：

  [EN] GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY
  [FR] COMPOSES MODULATEURS DE RECEPTEURS DE GLUCOCORTICOIDE ET PROCEDES

  摘要：

  本文提供了式（I）的化合物及其药用可接受的衍生物。其中某些化合物是选择性糖皮质激素受体调节剂和/或选择性糖皮质激素结合剂。还提供了制备和使用这些化合物的方法，包括但不限于使用这些化合物治疗各种疾病。

  公开号：

  WO2005082909A1
• 作为产物：
  描述：

  C₃₁H₃₄N₂O₅S 在 对甲苯磺酸 作用下， 以 氯仿 为溶剂， 生成 (Z)-5-(2'-(3'-(piperidinocarbonyl)thienylmethylidene))-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline
  参考文献：
  名称：

  5(Z)-Benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators

  摘要：

  A series of 5-benzylidene-1,2-dihydro-2,2,4-trimetbyl-5H-1-aza-6-oxa-chrysenes was synthesized and profiled for their ability to act as selective glucocorticoid receptor modulators (SGRMs). The synthesis and structure-activity relationships for this series of compounds are presented. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.062

文献信息

• Glucocorticoid receptor modulator compounds and methods
  申请人：Zhi Lin

  公开号：US20070281959A1

  公开（公告）日：2007-12-06

  Disclosed herein are compounds of Formula I: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

  本文公开了I式化合物及其药物可接受的盐、酯、酰胺和前药。其中某些化合物是选择性糖皮质激素受体调节剂和/或选择性糖皮质激素结合剂。还公开了制备和使用这些化合物的方法，包括但不限于使用这些化合物治疗各种疾病的方法。
• Glucocorticoid Receptor Modulator Compounds and Methods
  申请人：Zhi Lin

  公开号：US20090105292A9

  公开（公告）日：2009-04-23

  Disclosed herein are compounds of Formula I: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

  本文公开了I式化合物及其药物可接受的盐，酯，酰胺和前药。其中某些化合物是选择性糖皮质激素受体调节剂和/或选择性糖皮质激素结合剂。还公开了制备和使用这些化合物的方法，包括但不限于使用这些化合物治疗各种疾病。
• Synthesis and Characterization of Nonsteroidal Glucocorticoid Receptor Modulators for Multiple Myeloma
  作者：Andrew R. Hudson、Steven L. Roach、Robert I. Higuchi、Dean P. Phillips、Reid P. Bissonnette、William W. Lamph、Jean Yen、Yongkai Li、Mark E. Adams、Lino J. Valdez、Angie Vassar、Catalina Cuervo、E. Adam Kallel、Catherine J. Gharbaoui、Dale E. Mais、Jeffrey N. Miner、Keith B. Marschke、Deepa Rungta、Andrés Negro-Vilar、Lin Zhi

  DOI：10.1021/jm070370z

  日期：2007.9.1

  Structure-activity relationship studies centered around 3 '-substituted (Z)-5-(2 '-(thienylmethylidene))1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinolines are described. A series of highly potent and efficacious selective glucocorticoid receptor modulators were identified with in vitro activity comparable to dexamethasone. In vivo evaluation of these compounds utilizing a 28 day mouse tumor xenograft model demonstrated efficacy equal to dexamethasone in the reduction of tumor volume.